Global CAR T-Cell Therapy Market Size

Car T-Cell Therapy Market Analysis

The CAR T-cell therapy market is expected to register a CAGR of more than 30% over the forecast period.

The COVID-19 pandemic has significantly impacted the CAR T-cell therapy market. As per an article published in November 2021 in PubMed, CAR T-cell therapy recipients were believed to be at high risk of poor outcomes from COVID-19 due to their severely immunocompromised state caused by prior lymphodepletion immunochemotherapy and CAR-T-cell therapy-related side effects such as B-cell depletion, hypogammaglobulinemia, and cytopenias. Such studies reflect that the onset of the COVID-19 pandemic reduced the number of patients undergoing CAR-T cell therapy, significantly impacting the demand for CAR-T-cell therapy. However, with the introduction of vaccines and uplifting lockdown restrictions, research and development activities have been resumed, and patient visits increased, reflecting that the market is expected to grow significantly in the coming period.

The market's growth can be attributed to the factors such as the increasing burden of cancer and the rise in research and development to develop CAR T-cell therapy. For instance, according to the Macmillan Cancer Support statistics updated in October 2022, the estimated number of people currently living with cancer in the UK are likely to rise to 3.5 million by 2025, 4 million by 2030, and 5.3 million by 2040. This estimation includes 1,010,310 number of males and 948,000 cases of females. Furthermore, as per a June 2021 update by the American Society of Clinical Oncology (ASCO), cancer cells are known to hide from the normal immune system, but through CAR T-cell therapy, scientists can make T cells better equipped to find and kill some cancer cells. Thus, the anticipated increase in cancer cases will drive the demand for CAR T-cell therapy in the coming period. Additionally, increasing research and development are contributing to market growth. For instance, in December 2021, Novartis reported the introduction of T-Charge, the company's next-generation CAR-T platform that will serve as the foundation for various new investigational CAR-T cell therapies in the Novartis pipeline. Furthermore, in January 2022, Bristol-Myers Squibb Company reported that Japan's Ministry of Health, Labour and Welfare approved Abecma (idecabtagene violence), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy, for the treatment of adult patients with relapsed or refractory (R/R) multiple myeloma. Such developments drive the demand for CAR T-cell therapies, thereby contributing to market growth.

Hence, due to the rise in cancer cases, and the increase in research and development in CAR T- cell therapy, the studied market is expected to witness growth over the forecast period. However, the high cost of developing CAR T-cell therapy is a major factor hindering market growth.